RGC — Regencell Bioscience Holdings Income Statement
0.000.00%
Last trade - 00:00- $8.21bn
- $8.21bn
- 38
- 22
- 50
- 29
Annual income statement for Regencell Bioscience Holdings, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.812 | 1.38 | 7.62 | 6.27 | 4.74 |
| Operating Profit | -0.812 | -1.38 | -7.62 | -6.27 | -4.74 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.812 | -1.35 | -7.59 | -6.06 | -4.36 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.812 | -1.35 | -7.59 | -6.06 | -4.36 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.812 | -1.35 | -7.45 | -5.87 | -4.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.812 | -1.35 | -7.45 | -5.87 | -4.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.003 | -0.015 | -0.012 | -0.009 |
| Dividends per Share |